Goldman Small Cap Research Publishes New Research Report on QSAM Biosciences, Inc.

Baltimore, Maryland—Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on QSAM Biosciences, Inc. (OTCQB – QSAM). The Company is developing next generation nuclear medicines for the treatment of cancer and related diseases. This report carries a $3.00 price target. To view the new research report, along with disclosures and disclaimers, or to download it in its entirety, please visit https://bit.ly/3nGUocI.

The Company’s flagship product, Cyclosam^®, is a clinical-stage bone seeking therapeutic radiopharmaceutical (RPT) designed to safely and specifically deliver targeted radiation therapy to kill cancer cells in and near the bone. In animal studies and a recent single patient human trial, this approach appears to improve efficacy and safety. QSAM plans to commence additional trials during 2021.

In the Opportunity Research report, analyst Rob Goldman discusses the upcoming research and development milestones for the therapy, and how the Company appears to be built for sale in the next 2-3 years.

Goldman commented, “QSAM is poised to emerge as a key player in bone cancer treatment and other related diseases and indications. RPT has significant advantages over existing therapies, such as chemotherapy and radiation. The market is huge, and its adoption along with M&A are on the rise. The market is expected to reach $9.6 billion in 2026, up from about $4.8 billion in 2018.”

“QSAM’s lead product represents multiple indications with a potential addressable market in the billions. Separately, QSAM is primed to be awarded Orphan Drug Status for its lead indication and possibly an expedited program status following strong studies and a single patient human trial,” noted Goldman.

Goldman concluded, “With multiple milestones ahead, our six-month $3.00 price target reflects a typical valuation for a biotech in QSAM’s development stage, with a $5.00 target later in 2021, as more milestones are achieved. Management’s collective experience rivals midcap biotechs, with experience getting products through FDA and negotiating successful exits. QSAM appears to be next on the list.”

About Goldman Small Cap Research: Founded in 2009by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.

Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

This press release contains excerpts of our most recently published company report on QSAM Biosciences, Inc. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from QSAM Biosciences, Inc. (“the Company”). The information includes authorized press releases or legal disclosures made in their filings with the U.S. Securities and Exchange Commission http://www.sec.gov.

Separate from the factual content of our report about the Company, we may from time to time include our own opinions about the Company, its business, markets, and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, sector or industry snapshot, podcast interview, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only.  Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. A Speculative Buy rating for our covered companies is defined as a company that we believe exhibits the potential to generate outsized returns despite inherent, above-average business, market, or financial risk. To download this research report or any of our research, view our disclosures and disclaimers, or for more information, visit www.goldmanresearch.com. Goldman Small Cap Research was compensated $7500 by a third party for the production and distribution of a research report, updates and associated press releases and distribution.

Goldman Small Cap Research
Rob Goldman, Analyst

410-609-7100

[email protected]